The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Lecce V D, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Direnzo V, et al.

PLoS One. 2016; 11(7):e0159214. Epub 2016 Jul 08. PMID: 27390865. Abstract